News 27.08.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited...
News 20.08.2024 August 19, 2024 - Zurich, Switzerland, Brussels, Belgium, and New York, US InSphero, a leading innovator in 3D Cell Culture and Organ-on-Chip technology, has announced a new collaboration with Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, and the Université Libre de Bruxelles (ULB) Center for Diabetes Research. With funding from...
News 08.08.2024 Schlieren (Zurich), Switzerland, August 8, 2024 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced financial results for the first half of 2024. Revenue from direct MagnetOs product sales were CHF 31.6 million compared to CHF 12.2 million in H1 2023. Total revenue...
News 02.08.2024 Saint-Herblain (France) and Schlieren (Zurich), August 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced that the companies have entered into a strategic partnership and exclusive licensing...
News 10.07.2024 Switzerland, 9 July 2024 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced positive interim analysis on efficacy from the Phase 2 clinical trial of its lead product denovoSkin™ in patients undergoing reconstructive skin surgery due to various conditions. Dr. Daniela Marino,...